Anhui Anke Biotechnology (SHE:300009) received approval from the Chinese drug administration to conduct clinical trials into a growth hormone drug, according to a Shenzhen Stock Exchange filing on Thursday.
The injection will be tested in babies considered small-for-gestational-age (SGA), a disease that affects infants' growth and development, the biotech company said.
The company's shares closed 3% higher on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.